1. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet 2016;387:1947–1956.

2. Ghanemi A, Yoshioka M, St-Amand J. Broken energy homeostasis and obesity pathogenesis: the surrounding concepts. J Clin Med 2018;7:453.

3. Gossmann M, Butsch WS, Jastreboff AM. Treating the chronic disease of obesity. Med Clin North Am 2021;105:983–1016.

4. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021;320:C375–C391.

5. Chang SS, Eisenberg D, Zhao L, et al. Chemerin activation in human obesity. Obesity (Silver Spring) 2016;24:1522–1529.

6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860–867.

8. Jeong SM, Jung JH, Yang YS, et al. 2023 obesity fact sheet: prevalence of obesity and abdominal obesity in adults, adolescents, and children in Korea from 2012 to 2021. J Obes Metab Syndr 2024;33:27–35.

9. Yang YS, Han BD, Han K, Jung JH, Son JW. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022;31:169–177.

10. Buchwald H. The evolution of metabolic/bariatric surgery. Obes Surg 2014;24:1126–1135.

11. Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021;30:81–92.

12. Kim KK, Haam JH, Kim BT, et al. Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr 2023;32:1–24.

13. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis 2022;18:1345–1356.

14. Kremen AJ, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg 1954;140:439–448.

15. International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). The 8th IFSO Global Registry Report. Napoli: IFSO, 2023. 16. Han SM, Kim WW. The 3-year results of laparoscopic sleeve gastrectomy for the treatment of Korean morbid obesity. J Korean Surg Soc 2007;73:400–405. 17. Ohta M, Ahn SM, Seki Y, et al. Ten years of change in bariatric/metabolic surgery in the Asia-Pacific region with COVID-19 pandemic: IFSO-APC national reports 2021. Obes Surg 2022;32:2994–3004.

18. Choi S, Lee SH, Hong JH. Analysis of surgical status and short- and long-term complications following insurance coverage of bariatric surgery. Goyang: National Health Insurance Service Ilsan Hospital, 2023;Aug. Report No.: NHIMC-2022-PR-029. 19. Park JY. Diagnosis and management of postoperative complications after sleeve gastrectomy. J Metab Bariatr Surg 2022;11:1–12.

20. Alvarenga ES, Lo Menzo E, Szomstein S, Rosenthal RJ. Safety and efficacy of 1020 consecutive laparoscopic sleeve gastrectomies performed as a primary treatment modality for morbid obesity. A single-center experience from the metabolic and bariatric surgical accreditation quality and improvement program. Surg Endosc 2016;30:2673–2678.

21. Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 2022;57:267–285.

22. Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric surgery survey 2018: similarities and disparities among the 5 IFSO chapters. Obes Surg 2021;31:1937–1948.

23. Lee DY, Lee CM. Surgical treatment for obesity. J Korean Med Assoc 2022;65:417–422.

24. Cho YS, Park JH, Kim J, et al. Clinical outcomes of resectional Roux-en-Y gastric bypass, compared to sleeve gastrectomy for severe obesity. Obes Surg 2023;33:1338–1346.

25. Youk KM, Kim J, Cho YS, Park DJ. Gastric cancer after bariatric surgeries. J Metab Bariatr Surg 2022;11:20–29.

26. van de Laar AW, Emous M, Hazebroek EJ, Boerma EJ, Faneyte IF, Nienhuijs SW. Reporting weight loss 2021: position statement of the Dutch Society for Metabolic and Bariatric Surgery (DSMBS). Obes Surg 2021;31:4607–4611.

27. van de Laar AW, Acherman YI. Weight loss percentile charts of large representative series: a benchmark defining sufficient weight loss challenging current criteria for success of bariatric surgery. Obes Surg 2014;24:727–734.

28. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 2018;319:255–265.

29. Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS Randomized clinical trial. JAMA 2018;319:241–254.

30. Wölnerhanssen BK, Peterli R, Hurme S, et al. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg 2021;108:49–57.

31. Salminen P, Grönroos S, Helmiö M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y Gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg 2022;157:656–666.

32. van Rijswijk AS, van Olst N, Schats W, van der Peet DL, van de Laar AW. What is weight loss after bariatric surgery expressed in percentage total weight loss (%TWL)? A systematic review. Obes Surg 2021;31:3833–3847.

33. Kim JC, Kim MG, Park JK, et al. Outcomes and Adverse Events After Bariatric Surgery: An Updated Systematic Review and Meta-analysis, 2013–2023. J Metab Bariatr Surg 2023;Dec. 12(2):76–88.

34. Park JY, Heo Y, Kim YJ, et al. Long-term effect of bariatric surgery versus conventional therapy in obese Korean patients: a multicenter retrospective cohort study. Ann Surg Treat Res 2019;96:283–289.

35. Heo YS, Park JM, Kim YJ, et al. Bariatric surgery versus conventional therapy in obese Korea patients: a multicenter retrospective cohort study. J Korean Surg Soc 2012;83:335–342.

36. Park DJ, An S, Park YS, et al. Bariatric surgery versus medical therapy in Korean obese patients: prospective multicenter nonrandomized controlled trial (KOBESS trial). Ann Surg Treat Res 2021;101:197–205.

37. Cho YM. A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery. Diabetes Metab J 2014;38:406–415.

38. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 2012;135:247–278.

39. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741–749.

40. Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab 2015;21:369–378.

41. Ahn CH, Chae S, Oh TJ, Hwang D, Cho YM. Dynamic adaptive changes of the ileum transposed to the proximal small intestine in rats. Obes Surg 2019;29:2399–2408.

42. Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877.

43. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014;2014:CD003641.

44. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017;377:1143–1155.

45. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641–651.

46. Park CH, Nam SJ, Choi HS, et al. Comparative efficacy of bariatric surgery in the treatment of morbid obesity and diabetes mellitus: a systematic review and network meta-analysis. Obes Surg 2019;29:2180–2190.

47. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.

48. McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) bariatric study. JAMA Surg 2020;155:e200087.

49. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA 2020;324:879–887.

50. Hur KY, Moon MK, Park JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J 2021;45:461–481.

51. Ji G, Li P, Li W, et al. The effect of bariatric surgery on asian patients with type 2 diabetes mellitus and body mass index 2: a systematic review and meta-analysis. Obes Surg 2019;29:2492–2502.

52. Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis 2013;9:379–384.

53. Oh TJ, Lee HJ, Cho YM. East Asian perspectives in metabolic and bariatric surgery. J Diabetes Investig 2022;13:756–761.

54. Kim JH, Pyo JS, Cho WJ, Kim SY. The effects of bariatric surgery on type 2 diabetes in Asian populations: a meta-analysis of randomized controlled trials. Obes Surg 2020;30:910–923.

55. Ohta M, Seki Y, Ohyama T, et al. Prediction of long-term diabetes remission after metabolic surgery in obese East Asian patients: a comparison between ABCD and IMS scores. Obes Surg 2021;31:1485–1495.

56. Courcoulas AP, King WC, Belle SH, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg 2018;153:427–434.

57. Puzziferri N, Roshek TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014;312:934–942.

58. Lee Y, Doumouras AG, Yu J, et al. Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass: a systematic review and meta-analysis of weight loss, comorbidities, and biochemical outcomes from randomized controlled trials. Ann Surg 2021;273:66–74.

59. Hu Z, Sun J, Li R, Wang Z, et al. A comprehensive comparison of LRYGB and LSG in obese patients including the effects on QoL, comorbidities, weight loss, and complications: a systematic review and meta-analysis. Obes Surg 2020;30:819–827.

60. Ji Y, Lee H, Kaura S, et al. Effect of bariatric surgery on metabolic diseases and underlying mechanisms. Biomolecules 2021;11:1582.

61. Barchetta I, Cimini FA, Leonetti F, et al. Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes. J Clin Endocrinol Metab 2018;103:2253–2260.

62. Livadariu R, Timofte D, Trifan A, et al. Vitamin D deficiency, a noninvasive marker of steatohepatitis in patients with obesity and biopsy proven nonalcoholic fatty liver diseasE. Acta Endocrinol (Buchar) 2018;14:76–84.

63. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023.

64. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–378e5quiz e14–e15.

65. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015;149:379–388quiz e15–e16.

66. Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014;260:893–898discussion 898–899.

67. Chauhan M, Singh K, Thuluvath PJ. Bariatric surgery in NAFLD. Dig Dis Sci 2022;67:408–422.

68. Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg 2015;25:2280–2289.

69. Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040–1060e11.

70. Umeda LM, Pereira AZ, Carneiro G, Arasaki CH, Zanella MT. Postprandial adiponectin levels are associated with improvements in postprandial triglycerides after Roux-en-Y gastric bypass in type 2 diabetic patients. Metab Syndr Relat Disord 2013;11:343–348.

71. Osto E, Doytcheva P, Corteville C, et al. Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation 2015;131:871–881.

72. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021;143:e984–e1010.

73. Fisher DP, Johnson E, Haneuse S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018;320:1570–1582.

74. Doumouras AG, Wong JA, Paterson JM, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease:: a population-based retrospective cohort study. Circulation 2021;143:1468–1480.

75. Climent E, Goday A, Pedro-Botet J, et al. Laparoscopic Rouxen-Y gastric bypass versus laparoscopic sleeve gastrectomy for 5-year hypertension remission in obese patients: a systematic review and meta-analysis. J Hypertens 2020;38:185–195.

76. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.

77. Tan SC, Yang HC, Lim SC. Anatomy and pathophysiology of upper airway obstructive sleep apnoea: review of the current literature. Sleep Med Res 2021;12:1–8.

78. Pannain S, Mokhlesi B. Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism. Best Pract Res Clin Endocrinol Metab 2010;24:745–761.

79. Lee S, Byun JI, Choi SI, Shin WC. Metabolic effect of obstructive sleep apnea in patients undergoing bariatric surgery. J Sleep Med 2022;19:59–64.

80. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA 2020;323:1389–1400.

81. Locke BW, Gomez-Lumbreras A, Tan CJ, et al. The association of weight loss from anti-obesity medications or bariatric surgery and apnea-hypopnea index in obstructive sleep apnea. Obes Rev 2024;25:e13697.

82. Al Oweidat K, Toubasi AA, Tawileh RBA, Tawileh HBA, Hasuneh MM. Bariatric surgery and obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath 2023;27:2283–2294.

83. Currie AC, Kaur V, Carey I, et al. Obstructive sleep apnea remission following bariatric surgery: a national registry cohort study. Surg Obes Relat Dis 2021;17:1576–1582.

84. Bae EK, Lee YJ, Yun CH, Heo Y. Effects of surgical weight loss for treating obstructive sleep apnea. Sleep Breath 2014;18:901–905.

85. Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022;10:668–680.

86. Morin-Papunen L. Bariatric surgery in women with PCOS and obesity. Lancet 2024;403:2456–2457.

87. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602–1618.

88. Hu L, Ma L, Xia X, et al. Efficacy of bariatric surgery in the treatment of women with obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2022;107:e3217–e3229.

89. Samarasinghe SNS, Leca B, Alabdulkader S, et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. Lancet 2024;403:2489–2503.

90. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 2023;189:G43–G64.

91. Wiggins T, Antonowicz SS, Markar SR. Cancer risk following bariatric surgery-systematic review and meta-analysis of national population-based cohort studies. Obes Surg 2019;29:1031–1039.

92. Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA 2022;327:2423–2433.

93. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741–752.

94. Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet 2021;397:1830–1841.

95. Kauppila JH, Tao W, Santoni G, et al. Effects of obesity surgery on overall and disease-specific mortality in a 5-country population-based study. Gastroenterology 2019;157:119–127e1.